Cost effectiveness of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in a Middle-Income Country, Turkey: Results of a Prospective Multicenter Study

Basit Öğe Kaydı
dc.contributor.authorOzmen, Vahit
dc.contributor.authorCakar, Burcu
dc.contributor.authorGokmen, Erhan
dc.contributor.authorOzdogan, Mustafa
dc.contributor.authorGuler, Nilufer
dc.contributor.authorUras, Cihan
dc.contributor.authorOk, Engin
dc.date.accessioned2024-04-24T17:25:06Z
dc.date.available2024-04-24T17:25:06Z
dc.date.issued2019
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjective: Breast cancer is a heterogenous disease, and genetic profiling helps to individualize adjuvant treatment. The Oncotype DX is a validated test to predict benefit of adjuvant systemic treatment. The aims of this study are to determine the costs of chemotherapy in government hospitals in Turkey and evaluate the cost-effectiveness of the Oncotype DX from the national insurance perspective. Materials and Methods: A Markov model was developed to make long term projections of distant recurrence, survival, quality adjusted life expectancy, and direct costs for patients with ER+, HER2-, node-negative or up to 3 node-positive early stage breast cancer. Turkish decision impact study patient data were captured for model reference. In that study, ten academic centers across Turkey participated in a prospective trial. Of 165 patients with pT1-3, pN0-N1mic, ER-positive, and HER-2 negative tumors, 57% had low recurrence score (RS), 35% had intermediate RS, and 8% had high RS, respectively. The overall rate of change in chemotherapy treatment decisions following Oncotype DX was 33%. Results: The cost of adjuvant chemotherapy in public hospitals was estimated at $3.649, and Oncotype Dx test was $5.141. Based on the cost-effectiveness analysis, Oncotype DX testing was estimated to improve life expectancy (+0.86 years) and quality-adjusted life expectancy (+0.68 QALYs) versus standard care. The incremental cost-effectiveness ratio (ICERs) of Oncotype DX was estimated to be $7207.9 per QALY gained and $5720.6 per LY gained versus current clinical practice. Conclusion: As Oncotype DX was found both cost-effective and life-saving from a national perspective, the test should be introduced to standard care in patients with ER+, HER-2 negative early-stage breast cancer in Turkey.en_US
dc.identifier.doi10.5152/ejbh.2019.4761
dc.identifier.endpage190en_US
dc.identifier.issn2587-0831
dc.identifier.issue3en_US
dc.identifier.pmid31312795
dc.identifier.scopus2-s2.0-85077458303
dc.identifier.scopusqualityQ2
dc.identifier.startpage183en_US
dc.identifier.trdizinid368876
dc.identifier.urihttps://doi.org/10.5152/ejbh.2019.4761
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/368876
dc.identifier.urihttps://hdl.handle.net/11468/19937
dc.identifier.volume15en_US
dc.identifier.wosWOS:000473357300009
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofEuropean Journal of Breast Health
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectEarly Breast Canceren_US
dc.subjectGenetic Profilingen_US
dc.subjectOncotype-Dxen_US
dc.subjectCosten_US
dc.subjectMarkov Modelen_US
dc.titleCost effectiveness of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in a Middle-Income Country, Turkey: Results of a Prospective Multicenter Studyen_US
dc.titleCost effectiveness of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in a Middle-Income Country, Turkey: Results of a Prospective Multicenter Study
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu